ARKANSAS REGISTER



Transmittal Sheet

Use only for **FINAL** and **EMERGENCY RULES**

Secretary of State

John Thurston

500 Woodlane, Suite 026 Little Rock, Arkansas 72201-1094 (501) 682-5070



www.sos.arkansas.gov

For Office Use Only:		
Effective Date	Code Number	
Name of Agency Arkansas Department	of Health	
Department Pharmacy Services		
Contact Laura Shue	_ _{E-mail} _Laura.Shue@arkansas.gov_ _{Phone}	_e 501-661-2297
Statutory Authority for Promulgating Rule	es § 20-7-109 et seq.	
Rule Title: Rules Pertaining to	the List of Controlled Substances	
Intended Effective Date		Date
Emergency (ACA 25-15-204)	Legal Notice Published	8/25/19
10 Days After Filing (ACA 25-15-204)	Final Date for Public Comment	9/26/19
Other	Reviewed by Legislative Council	5/15/20
(Must be more than 10 days after filing date.)	Adopted by State Agency	8/1/19
Electronic Copy of Rule e-mailed from: (Required	l under ACA 25-15-218)	
	ue@arkansas.gov	6/3/20
Contact Person	E-mail Address	Date
I Hereby Certif	ON OF AUTHORIZED OFFICER y That The Attached Rules Were Adopted tansas Administrative Act. (ACA 25-15-201 et. seq.)
	uu K. Suue Signature	
501-661-2297	Laura.Shue@arkansas.gov	
Phone Number	E-mail Address General Counsel	
4	Title	
	6/3/20	

List Of Controlled Substances



For the State Of Arkansas Pursuant to the provisions of Arkansas Code Annotated \S 5-64-201 and \S 5-64-216 of the laws of the State of Arkansas, the Director of the Arkansas Department of Health or duly authorized agent, as specified by law, is giving public notice of the publication of the List of Controlled Substances for the State of Arkansas.

Due consideration has been given applicable federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

Based on these considerations the attached listing of the Schedule of Controlled Substances and the corresponding drugs that are included in each schedule is hereby promulgated by the Director of the Arkansas Department of Health as the List of Controlled Substances for the State of Arkansas.

Each controlled substance or basic class thereof has been assigned an "Administration Controlled Substance Code Number" for purposes of identification. These numbers are for internal management and are used as a means to identify substances with complex and cumbersome chemical names.

Next to the code number is the date the substance was placed in schedule by the Director of the Arkansas Department of Health.

I, Shane David, Pharm.D., Section Chief of Pharmacy Services for the Arkansas Department of Health, do hereby certify that the documents attached hereto are true and correct copies of the current List of Controlled Substances adopted by the Arkansas State Board of Health in accordance with Arkansas state law.

Shane David, Pharm.D., Section Chief Pharmacy Services Branch

STATE OF ARKANSAS
COUNTY OF SALINE

I, Marci Middleton, do hereby certify that Shane David, Pharm.D., well known to me, appeared before me and signed the above referenced document.

Sworn and subscribed to before me this

ady of

Notary Public

04-25-2025 My commission expires MARCI MIDDLETON MY COMMISSION # 12403633 EXPIRES: April 25, 2025 Saline County

ARKANSAS DEPARTMENT OF HEALTH

LIST OF CONTROLLED SUBSTANCES

SECTION I AUTHORITY

The following scheduling of these controlled substances has been hereby promulgated pursuant to Arkansas Stat. Ann. \$5-64-201 and \$5-64-216.

SECTION II PURPOSE

Due consideration has been given applicable Federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

SECTION III GENERAL REQUIREMENTS

(Attached copy of the listing of scheduling of controlled substances)

SECTION IV REPEAL

All lists of schedules of controlled substances in conflict herewith are hereby repealed.

CERTIFICATION

This will certify the following list of scheduling of controlled substances was adopted by the Arkansas State Board of Health at a session of the Board held in Little Rock, Arkansas on the 1st day of August, 2019, and after a Public Hearing on the 26th day of September, 2019, held in Little Rock, Arkansas, at the State Department of Health Building.

Nathaniel Smith, M.D., MPH

Director, Arkansas Department of Health

ARTICLE II

Schedule I

(a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) Opiates: (Narcotic Drugs) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, salts is possible within the specific chemical designation (for purposes of 3-methylthiofentanyl only, the term isomer includes the optical and geometric isomers):

the c	ptical and geometric isomers):	
(1)	Acetyl-alpha-methylfentanyl(N-[1-[1-methyl-2-	
	phenethyl)-4-piperidinyl]-N-phenylacetamide)	9815-(2-86)
(2)	Acetylmethadol	9601*
(3)	Allylprodine	
(4)	Alphacetylmethadol (except Levo-alphacetylmethadol	
	(LAAM)	9603*
(5)	Alphameprodine	9604*
(6)	Alphamethadol	9605*
(7)	Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phen	
	ethyl-4-piperidyl]propronanilide; 1-(1-methyl-	
	2-phenylethyl) -4 (N-propanilido) piperidine)	9814-(6-82)
(8)	Alpha-methylthiofentanyl(N-[1-methyl-2-(2thienyl)	
	ethyl-4-piperidinyl]-N-phenylpropanamide)	9832 - (2-86)
(9)	Benzethidine	
(10)	Betacetylmethadol	9607*
(11)	Beta-hydroxyfentanyl(N-[1-(2-hydroxy-2-phenethyl)	
	-4-piperidinyl[]-N-phenylpropanamide)	9830-(2-86)
(12)	Beta-hydroxy-3-methylfentanyl	
	[other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl	-
	4-piperidinyl]-N-phenylpropamamide]	9831-(2-86)
(13)	Betameprodine	9608*
(14)	Betamethadol	9609*
(15)	Betaprodine	9611*
(16)	Clonitazene	
(17)	Dextromoramide	9613*
(18)	Diampromide	9615*
(19)	Diethylthiambutene	9616*
(20)	Difenoxin	
(21)	Dimenoxadol	
(22)	Dimepheptanol	9618*
(23)	Dimethylthiambutene	9619*
(24)	Dioxaphetyl butyrate	9621*
(25)	Dipipanone	9622*
(26)	Ethylmethylthiambutene	9623*
(27)	Etonitazene	
(28)	Etoxeridine	
(29)	Furethidine	
(30)	Hydroxypethidine	962/*
(31)	Ketobemidone	
(32)	Levomoramide	9629*
(33)	Levophenacylmorphan	9631*
(34)	3-Methylfentanyl (N-[3-Methyl-1-(2-phenylethyl)-4-	0010 /10 05
	piperidyl]-N-Phenylpropanamide)	9813-(10-85)

(35)	3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)	
	ethyl-4-piperidinyl]-N-phenylpropanamide)	9833-(2-86)
(36)	Morpheridine	
(37)	MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)	9661-(10-85)
(38)	Noracymethadol	9633*
(39)	Norlevorphanol	9634*
(40)	Normethadone	
(41)	Norpipanone	9636*
(42)	Para-fluorofentanyl (N-[4-fluorophenyl)-N-[1-(2-	
()	phenenthyl)-4-piperindinyl]propananmide	9812-(11-86)
(43)	PEPAP 1-(2-phenylethyl)-4-phenyl-4 acetyloxypiper-	3012 (11 00)
(45)	idine	9663-(10-85)
(44)	Phenadoxone	
(45)	Phenampromide	
(46)	Phenomorphan	
(47)	Phenoperidine	9641*
(48)	Piritramide	96/2*
(49)	Proheptazine	
(50)	Properidine	0644*
	Propiram	9644^
(51)		
(52)	Racemoramide	9645*
(53)	Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-	
	piperidinyl]-propanamide	
(54)	Tilidine	9750-(9-81)
(55)	Trimeperidine	9646*
(56)	Acetyl fentanyl N-(1-phenethylpiperidin-4-yl)	
(5.5)	-N-phenylacetamide	-9821
(57)	Butyryl fentanyl N-(1-phenethylpiperidin-4-yl)	0000
4.5.0.)	-N-phenylbutyramide	-9822
(58)	Beta-hydroxythiofentanyl N-{1-[2-hydroxy-2-	
	(thiophen-2-yl)ethyl]piperidin-4-yl}-N-	
0.11	phenylpropionamide	-9836
(59)	Acetyl fentanyl 4-methylphenethyl analog N-	
	$\{1-[2-(4-methylphenyl)ethyl]-4-piperidinyl\}-N-$	
	phenyl-acetamide monohydrochloride	
(60)	Valeryl fentanyl N-phenyl-N[1-(2-phenylethyl)	
	-4-piperidinyl]-pentanamide monohydrochloride	
(61)	Furanyl fentanyl N-(1-(2-phenylethyl)-	
	4-piperidinyl)-N-phenylfuran-2-carboxamide	9834
(62)	Isobutyryl fentanyl 2-methyl-N-phenyl-N-	
	[1-(2-phenylethyl)-4-piperidinyl]-propanamide	
	monohydrochloride	
(63)	Ocfentanil N-(2-fluorophenyl)-2-methoxy-N-[1-(2-	
, ,	phenylethyl)piperidin-4-yl]acetamide	9838
(64)	4-methoxy butyryl fentanyl N-(4-methoxyphenyl)-N	
(01)	-(1-phenethylpiperidin-4-yl)butyramide monohydro	
	chloride	
(65)	Para-fluorobutyryl fentanyl N-(4-fluorophenyl)-N-	
(00)	[1-(2-phenylethyl)-4-piperidinyl]-butanamide mono	
1.5.5	hydrochloride	,
(66)	Acetyl norfentanyl N-phenyl-N-4-piperidinyl-acetami	de
	monohydrochloride	
(67)	AH-7921 3,4-dichloro-N-[(ldimethylamino)cyclohexyl	
	methyl]benzamide	
(68)	W-18 1-(4-nitrophenylethyl)piperidylidene-2-(4-	
	chlorophenyl) sulfonamide	
(69)	W-15 1-phenylethylpiperidylidene-2-(4-chlorophenyl)	
	sulfonamide	
(70)	MT = 45 1-cyclohevyl-4-(1 2-diphenylethyl) ninerazine	

4-yl)-N-phenyltetrahydrofuran-2-carboxamide----- 9843

(c) Opium derivatives: (Narcotic Drugs) Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

LOII		
(1)	Acetorphine	9319*
(2)	Acetyldihydrocodeine	9051*
(3)	Benzylmorphine	9052*
(4)	Codeine methylbromide	9070*
(5)	Codeine-N-Oxide	9053*
(6)	Cyprenorphine	9054*
(7)	Desomorphine	9055*
(8)	Dihydromorphine	9145*
(9)	Drotebanol	9335*
(10)	Etorphine (except hydrochloride salt)	9056*
(11)	Heroin	9200*
(12)	Hydromorphinol	9301*
(13)	Methyldesorphine	9302*
(14)	Methyldihydromorphine	9304*
(15)	Morphine methylbromide	9305*
(16)	Morphine methylsulfonate	9306*
(17)	Morphine-N-Oxide	9307*
(18)	Myrophine	9308*
(19)	Nicocodeine	9309*
(20)	Nicomorphine	9312*
(21)	Normorphine	9313*
(22)	Pholodine	9314*
(23)	Thebacon	9315*
(24)	Mitragynine	2010
(25)	7-Hydroxymitragynine	
(20)	, mydroxymrcragymrne	

- (d) <u>Hallucinogenic substances</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substance, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purposes of this paragraph only, the term "isomer" includes the optical, position and geometric isomers):
 - (1) alpha-ethyltryptamine ------ 7249-(12-93) Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; alpha-ET; and AET.
 - (2) 4-bromo-2,5-dimethoxy-amphetamine ----- 7391* Some trade or other names: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; 4-bromo-2,5-DMA.
 - (3) 4-bromo-2,5-dimethoxyphenethylamine ----- 7392-(8-95) Some trade or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1 aminoethane; alpha-desmethyl DOB; 2C-B, Nexus.
 - (4) 2,5-dimethoxyamphetamine ----- 7396*

	Some trade or other names: 2,5-dimethoxy-alpha-	
/ E)	methylphenethylamine; 2,5-DMA.	7200 /2 001
(5)	2,5-dimethoxy-4-ethylamphetamine	/399-(3-88)
(6)	2,5-dimethoxy-4-(n)-propylthiophenethylamine	7348-(1-05)
(0)	Some trade or other names: 2C-T-7.	7540 (1 05)
(7)	4-methoxyamphetamine	7411*
(Some trade or other names: 4-methoxy-alpha-	, 111
	methylphenethylamine; paramethoxyamphetamine; PMA.	
(8)	5-methoxy-3,4-methylenedioxy-amphetamine	7401*
(9)	4-methyl-2,5-dimethoxyamphetamine	
131	Some trade and other names: 4-methyl-2,5-dimethoxy-	7333
	alphamethylphenethylamine; "DOM"; and "STP".	
(10)	3,4-methylenedioxy amphetamine	7400*
(11)	3,4-methylenedioxymethamphetamine	7405-(10-85)
(+ +)	Some trade or other names: MDMA)	, 100 (10 00)
(12)	3,4-methylenedioxy-N-ethylamphetamine	7404-(6-90)
(± 2)	Some trade or other names: N- ethy-alpha-methyl-3,4	,101 (0 50)
	(methylenedioxy) phenethylamine, N-ethyl MDA; MDE;	
	MDEA.	
(13)	N-hydroxy-3,4-methylenedioxyamphetamine	7402-(6-90)
(10)	Some trade or other names: N-hydroxy-alpha-methyl-3,	7102 (0 50)
	4 (methylenedioxy) phenethylamine; N-hydroxy MDA	
(14)	3,4,5-trimethoxy amphetamine	7390*
(15)	5-methoxy-n,n-dimethyltryptamine 5-MeO-DMT	
(16)	alpha-methyltryptamine	
(/	Some trade or other names: AMT	, 102 (, 007
(17)	Bufotenine	7433*
(/	Some trade and other names: 3-(beta-	
	Dimethylaminoethyl)-5-hydroxyindole; 3-(2-	
	dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin;	
	5-hydroxy-N, N-dimethyltryptamine; mappine.	
(18)	Diethyltryptamine	7434*
	Some trade or other names: N, N-Diethyltryptamine;	
	DET.	
(19)	Dimethyltryptamine	7435*
	Some trade or other names: DMT	
(20)	5-methoxy-N, N-diisopropyltryptamine	7439-(7-05)
	Some trade or other names: 5-MeO-DIPT.	
(21)	Ibogaine	7260*
	Some trade and other names: 7-Ethyl-6,6 beta; 7,8,9,	
	10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido	
	[1',2': 1,2] azepino [5,4-b] indole; Tabernanthe	
	iboga.	
(22)	Lysergic acid diethylamide	7315*
(23)	Mescaline	
(24)	Parahexyl	7374-(7-83)
	Some trade or other names: 3-Hexyl-1-hydroxy-	
	7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo	
	[b,d] pyran; Synhexyl.	
(25)	Peyote	7415*
	Meaning all parts of the plant presently classified	
	botanically as Lophophora williamsii Lemaire, whether	•
	growing or not; the seeds thereof; any extract from	
	any part of such plant; and every compound,	
	manufacture, salts, derivative, mixture or	
	preparation of such plant, its seeds or extracts.	
(0.5)	(Interprets 21 USC 812 (c), Schedule I (c) (12)).	7.400
(26)	N-ethyl-3-piperidyl benzilate	/482*

(27)	N-methyl-3-piperidyl benzilate	7484*
(28)	Psilocybin	
(29)	Psilocyn	7438*
(30)	Ethylamine Analog of phencyclidine	7455*
	Some trade or other names:	
	N-ethyl-1-phenylcyclohexylamine,	
	(phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)	
	ethylamine; cyclohexamine; PCE.	
(31)	Pyrrolidine Analog of phencyclidine	7458*
	Some trade or other names: 1-(1-phenylcyclohexyl)-	
	pyrrolidine; PCPy; PHP	
(32)	Thiophene Analog of phencyclidine	7470*
	Some trade or other names: 1-[1-(2-thienyl)	
	cyclohexyl] Piperidine; 2-Thienyl analog of	
	phencyclidine; TPCP; TCP.	
(33)	1-[1-(2-Thienyl)cylcohexyl]pyrrolidine	7473-(9-89)
100/	Some other trade or other names: TCPy.	
(34)	N, N-Diallyl-5-Methoxytryptamine; Some trade or other	names:
(51)	5-MeO DALT; 5-Methoxy-DALT.	11011100
(35)	2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)	1
(33)	methyl]ethanamine; 25C-NBOMe	
(36)	2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)	
(30)	methyl]ethanamine; 25I-NBOMe	
(37)	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine; 2C-E	7509
(38)	2-(2,5-Dimethoxy-4-methylphenyl)ethanamine; 2C-D	
(39)	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine; 2C-C	
(40)	2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine; 2C-I	
(41)	2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine;	7310
(41)	2C-T-2	7395
(42)	2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine;	7303
(42)	2C-T-4	7532
(43)	2-(2,5-Dimethoxyphenyl)ethanamine; 2C-H	
(44)	2-(2,5-DimethoxyPhenyl)ethanamine; 2C-N	7521
	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine;	1321
(45)	2C-P	7524
116	2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)e	
(46)	25B-NBOMe	Lilanamine,
(47)		.11
(47)	2-[[[2-(4-bromo-2,5-dimethoxyphenyl)ethyl]amino]methy	/I]-pnenol;
	25B-NBOH	
(48)	2-[[[2-(4-iodo-2,5-dimethoxyphenyl)ethyl]amino]methy	L]-pnenol;
	25I-NBOH	
(49)	2-(4-ethyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)	
	methyl]ethanamine; 25E-NBOMe	
(50)	2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)	
	methyl]ethanamine; 25H-NBOMe	
(51)	2-[[[2-(4-chloro-2,5-dimethoxyphenyl)ethyl]amino]meth	nyl]-
	phenol; 25C-NBOH	
(52)	2-[[[2-(2,5-dimethoxyphenyl)ethyl]amino]methyl]-pheno	ol;
	25H-NBOH	

- (e) <u>Depressants</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
 - (1) Phenazepam
 - (2) gamma-hydroxybutyric acid (some other names include

GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxydutanoic acid; sodium oxybate; sodium oxybutyrate), and its known precursors and analogs -- 2010-(2-01) Mecloqualone ----- 2572* (3)Methaqualone ----- 2565* (4)(5)Etizolam Stimulants: (a) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: (1) Cathinone ----- 1235-(3-88) (+) CIS-4-Methylaminorex [(+)CIS-4,5-dihydro-4-(2)methyl-5-phenyl-2-oxazolamine] ----- 1590-(6-90) Fenethylline ----- 1503-(9-81) (3)(4) N-Benzylpiperazine----- 7493-(1-05) Some trade or other names: BZP, 1-Benzylpiperazine (5) N-ethylamphetamine ----- 1475-(6-82) (6) N-[1-(1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts and salts of isomers ----- 9818-(2-86) (7) N-[1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanmide (thenylfentanyl), its optical isomers, salts and salts of isomers ----- 9834-(2-86) (8) N, N, Dimethylamphetamine (some other names: N, N Alpha-trimethylbenzeneethanamine; N, N, Alphatrimethylphenethylamine), its salts, optical isomers, and salts of optical isomers ----- 1480-(2-89) (9) Methcathinone (some other names: 2-Methylamine-Proprophenone, alpha (methylamino) -Proprophenone, 2 (methylamino)-1-phenylpropan-1-one, alpha-N-Methylaminopropiophenone, monomethylpropion, ephedrone, N-methylcathinone, methycathinone, AL-464, AL-422, AL-463 and UR-1431), its salts, optical isomers and salts of optical isomers ----- 1237-(12-93) Aminorex (some other names: aminoraphen, 2-amino-5 (10)phenyl-2-oxazoline, or 4,5 dihyrdo-5-phenyl-2oxazolamine, its salts, optical isomers, and salts of optical isomers ----- 1585-(12-93) (11) Methyl-N-ethylcathinone (MEC) (b) Any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of the following substances' analogs, salts, isomers, and salts of isomers when the existence of the analogs, salts, isomers, and salts of isomers is possible within the specific chemical designation, with the following chemical structure is included in Schedule I: (1) 4-Methylmethcathinone (Mephedrone) ----- 1248-(3-11) (2) Methylenedioxypyrovalerone (MDPV) ----- (3-11) 3,4-Methylenedioxy-N-methylcathinone (Methylone)---- 7540-(3-11) (3) (4) 4-Methoxymethcathinone -----(5) 3-Fluoromethcathinone (3-11)(6) 4-Fluoromethcathinone or -----(3-11)(7) 1-(1,3-benzodioxol-5-yl)-2-methylamino)butan-1-one (Butylone) (8) Alpha-Pyrrolidinopentiophenone (Alpha-PVP) (9) 4-methyl-N-ethylcathinone (4-MEC) (10) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP)

(11) 2-(methylamino)-1-phenylpentan-1-one (Pentedrone)

- (12) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (Pentylone,MBDP)
- (13) 4-fluoro-N-methylcathinone (4-FMC, Flephedrone)
- (14) 3-fluoro-N-methylcathinone (3-FMC)
- (15) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (Naphyrone)
- (16) Alpha-pyrrolidinobutiophenone ([Alpha]-PBP) or
- (17) A compound, unless listed in another schedule or a legend drug, that is structurally derived from 2-Amino-phenyl-1-propanone by modification or by substitution:
 - (A) In the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one (1) or more other univalent substituents;
 - At the 3-position with an alkyl substituent; or
 - (C) At the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.
- (18) N-Ethylpentylone, or 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-

Schedule II

- Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the Controlled Substances Code Number set forth opposite it.
- (b) Narcotic Drugs: Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:
 - (1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone and naltrexone and their respective salts, but including the following:
 - (1) Raw opium ----- 9600*
 - Opium extracts ----- 9610*
 - Opium fluid extracts ----- 9620*
 - Powdered opium ----- 9639* (4)
 - Granulated opium ----- 9640* (5)
 - Tincture of opium ----- 9630* (6)
 - Codeine ----- 9050* (7)
 - (8) Dihydroetorphine----- 9334*
 - (9) Ethylmorphine ----- 9190*
 - (10) Etorphine hydrochloride ----- 9059*
 - Hydrocodone ----- 9193*
 - (11)Hydromorphone ----- 9150* (12)
 - (13) Metopon ----- 9260*
 - (14) Morphine ----- 9300*
 - (15) Oripavine ------ 9330*(9-07)
 - (16) Oxycodone ----- 9143*
 - (17) Oxymorphone ----- 9652*
 - Thebaine ----- 9333* (18)
 - (19) Tapentadol ----- 9780-(5-09)
 - (2) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (b) (1) of this section, except that these substances shall not include the isoquinoline alkaloids of opium.*

- (3) Opium poppy and poppy straw.*
- (4) Coca leaves (9040) and any salt, compound, derivative, or preparation of coca leaves, (including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine.*
- (5) Concentrate or poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrine alkaloids of the opium poppy), 9670.*
- (c) Opiates: (Narcotic Drugs) Unless specifically excepted or unless in another schedule, any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designations:

HUCTOH	0.	
(1)	Alfentanil	9737-(2-87)
(2)	Alphaprodine	9010*
(3)	Anileridine	
(4)	Bezitramide	
(5)	Bulk Dextropropoxyphene (non-dosage forms)	9273-(9-81)
(6)	Carfentanil	9743-(9-88)
(7)	Dihydrocodeine	9120*
(8)	Diphenoxylate	9170*
(9)	Fentanyl	9801*
(10)	Isomethadone	9226*
(11)	Levo-alphacetylmethadol (LAAM)	9648-(12-93)
(12)	Levomethorphan	9210*
(13)	Levorphanol	
(14)	Metazocine	
(15)	Methadone	9250*
(16)	Methadone-Intermediate, 4-cyano-2-	
	dimethylamino-4, 4-diphenyl butane	9254*
(17)	Moramide-Intermediate, 2-methyl-3-	
	morpholino-1, 1-diphenylpropane-	
	carboxylic acid	
(18)	Pethidine (Meperidine)	9230*
(19)	Pethidine-Intermediate-A, 4-cyano-1-	
	methyl-4-phenylpiperidine	9232*
(20)	Pethidine-Intermediate-B, ethyl-4-	
	phenylpiperidine-4-carboxylate	9233*
(21)	Pethidine-Intermediate-C, 1-methyl-4-	
	phenylpiperidine-4-carboxylic acid	9234*
(22)	Phenazocine	9715*
(23)	Piminodine	9730*
(24)	Racemethorphan	9732*
(25)	Racemorphan	9733*
(26)	Remifentanil	
(27)	Sufentanil	9740-(9-81)

- (d) <u>Stimulants:</u> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:
 - (1) Amphetamine, its salts, optical isomers, and salts of its optical isomers ------ 1100*
 - (2) Methamphetamine, its salts, isomers, and salts

	of its isomers	1105*
(3)	Lisdexamefetamine	1205*(7-07)
(4)	Phenmetrazine and its salts	1631*
(5)	Methylphenidate	1724*

- (e) <u>Depressants</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
 - (1) Amobarbital ----- 2125*
 - (2) Glutethimide ----- 2550-(2-91)
 - (3) Pentobarbital ----- 2270*
 - (4) Phencyclidine ----- 7471*
 - (5) Secobarbital ----- 2315*

(f) Hallucinogenic Substances:

- (2) Dronabinol in an oral solution in a drug product approved for marketing by the U.S.Food and Drug Administration; [(-)-delta-9-trans-tetrahydrocannabinol(delta-9-THC)].----7365
- (g) <u>Immediate Precursor</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:
 - (1) Immediate precursor to Amphetamine and Methamphetamine:
 - (2) Immediate precursor to Phencyclidine (PCP):
 - (i) 1-phenylcyclohexylamine ----- 7460*
 - (ii) 1-piperidinocyclohexanecarbonitrile (PCC) ----- 8603*
 - (3) Immediate precursor to Fentanyl:
 - (i) 4-anilino-N-phenethylpiperidine(ANPP) ----- 8333*(08-10)

Schedule III

- (a) Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.
- (b) <u>Stimulants:</u> Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
 - (1) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 308.32,

(2) (3) (4) (5)	and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances————————————————————————————————————	1228* 1645* 1647*
schedule, a	pressants: Unless specifically excepted or unless list ny material, compound, mixture, or preparation which could the following substances having a depressant effect of tem:	ontains any
(1)	Any compound, mixture, or preparation containing: (i) Amobarbital (ii) Secobarbital (iii) Pentobarbital (iv) Embutramide or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.	2316* 2271*
(2)	Any suppository dosage form containing: (i) Amobarbital (ii) Secobarbital (iii) Pentobarbital or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.	2316*
(3) (4) (5)	Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof Chlorhexadol	2510*
(6)	Act	
(11) (12) (13)	Tiletamine and zolazepam or any salt thereof Some trade or other name for a tiletamine- zolazepam combination product: Telazol. Some trade or other names for tiletamine: -2(ethylamino)-2-(2-thienyl)-cyclohexanone. Some trade or other names for zolazepam: -4(2-fluorophenyl)-6,8-dihydro-1,3,8,- trimethylpyrazolo-[3,4-e] [1,4,]-diazepin-7 (1-H)-one. flupyrazapon.	7310* 2575* 2600* 2605* 2610* 7295-(3-88)
(14)	Perampanel	2261-(11-13)
(d) <u>Nal</u>	orphine	9400*

- (e) Narcotic drugs: Unless specifically excepted or unless listed in another schedule: (1) any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: (i) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium ----- 9803* (ii) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ----- 9804* (iii) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts ----- 9807* Not more than 300 milligrams of ethylmorphine (iv) per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ----- 9808* Not more than 500 milligrams of opium per 100 (V) milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts ----- 9809* (vi) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ----- 9810* (2) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth below: Buprenorphine ----- 9064-(6-85) (i) (10-02 Transfer) (ii) Reserved (f) Anabolic Steroids: Unless specifically excepted or unless listed in
- - (1) Boldenone;
 - (2) Boldione; (01-10)
 - (3) Chlorotestosterone (4-chlortestosterone);
 - (4) Clostebol;
 - (5) Dehydrochlormethyltestosterone;
 - (6) Desoxymethyltestosterone (01-10)
 - (7) Dihydrotestosterone (4-dihydrotestosterone);
 - (8) Drostanolone;
 - (9) Ethylestrenol;
 - (10) Fluoxymesterone;
 - (11) Formebulone (formebolone);

```
(12) Mesterolone;
   (13) Methandienone, Methandrostenolone;
   (14) Methandranone;
  (15) Methandriol;
  (16) Methenolone;
  (17) Methyltestosterone;
  (18) Mibolerone;
  (19) Nandrolone;
  (20) 19-Nor-4,9(10)-Androstadienedione (01-10)
  (21) Norethandrolone;
  (22) Oxandrolone;
  (23) Oxymesterone;
  (24) Oxymetholone;
  (25) Stanolone;
  (26) Stanozolol;
  (27) Testolactone;
  (28) Testosterone;
  (29) Trenbolone
  (30) Prostanozol-----(8-12)
  (31) Methasterone----(8-12);
  (32) Any salt, ester, or isomer of a drug or
      substance described or list in this paragraph,
      if that salt, ester, or isomer promotes muscle
      growth.
(1) Exempt anabolic steroid products: Compounds,
  mixtures, or preparations that contain an anabolic
  steroid that have been exempted by the Director:
  (1) Andro-Estro 90-4----- 0536-1605
  (2) Androgyn L.A.---- 0456-1005
  (3) Component E-H in Process Pellets----- Ivy Labs Inc.
  (4) Component E-H in Process Granulation----- Ivy Labs Inc.
  (5) Component TE-S in process Granulation----- Ivy Labs Inc.
  (6) Component TE-S in process Pellets----- Ivy Labs Inc.
  (7) depANDROGYN----- 0456-1020
  (8) Depo-Testadiol----- 0009-0253
  (9) DEPO-T.E.---- 52765-257
  (10) depTESTROGEN----- 51698-257
  (11) Duomone----- 52047-360
  (12) DUO-SPAN II----- 0684-0102
  (13) DURATESTRIN---- 43797-016
  (14) Essian----- Pharmaceutics
  (15) Essian H.S.----- Pharmaceutics
  (16) Esterified Estrogens & Methyltestosterone, USP
      (0.625 mg/1.25mg)----- Interpharm
  (17) Esterified Estrogens & Methyltestosterone, USP
      (1.25mg/2.5mg)----- Interpharm
  (18) Esterified Estrogens & Methyltestosterone
      (0.625mg/1.25mg) Tablet----- ANDAPharm
  (19) Esterified Estrogens & Methyltestosterone
      (1.25mg/2.5mg) Tablet----- ANDAPharm
  (20) Estratest----- 0032-1026
  (21) Estratest HS----- 0032-1023
  (22) Menogen----- 59243-570
  (23) Menogen HS----- 59243-560
  (24) Methyltestosterone & Esterified Estrogens
      (2.5mg/1.25Mg)----- Lannett Co
  (25) Methyltestosterone & Esterified Estrogens (Half
```

		(27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (40) (41) (42) (43) (44) (45)	Strength) (1.25mg/0.625mg)	0525-0175 0046-0879 0046-0878 66576-231 66576-230 Syntex Animal Fort Dodge Fort Dodge 0536-9470 Alza Corp. 17314-4608 17314-4609 17314-2836 Alza Corp. Alza Corp. 54274-530 0182-3069 0814-7737
		(47)	Testosterone Enanthate/Estradiol Valerate injection	0182-3073
		(49)	injection Testosterone Enanthate/Estradiol Valerate	0364-6618
((2)	(51) Veter Anabo admir	injection	Allergan
		(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19)	Component E-H	01968327 021641-004 0211641-006 0211641-005 00093351 12799-807-07 Boehringer Ingelheim Ivy Lab. 0009-0434-01 06-0434-01 01968327 Rangen, Inc. 12799-810 12799-809 0856-3901

(20) Synovex Plus ----- 0856-3904 Tilapia Sex Reversal Feed (investigational) ----- Zeigier Bros.

If veterinary products that are granted exempted status are subsequently distributed with the intent that they be used in humans, the distribution would be subject to the criminal sanctions of the CSA despite the drugs' exempted status.

(g) Hallucinogenic substances:

Schedule IV

- (a) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.
- (b) <u>Narcotic drugs</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:
 - (1) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.----- 9167*
 - (2) Dextro propoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane) ---- 9278-(11-87)
- (c) <u>Depressants</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1)	Alprazolam	2882-(6-82)
(2)	Barbital	2145*
(3)	Bromazepam	2748-(1-85)
(4)	Camazepam	2749-(1-85)
(5)	Chloral betaine	2460*
(6)	Chloral hydrate	2465*
(7)	Chlordiazepoxide	2744*
(8)	Clobazam	2751-(1-85)
(9)	Clonazepam	2737*
(10)	Clorazepate	2768*
(11)	Clotiazepam	2752-(1-85)
(12)	Cloxazolam	2753-(1-85)
(13)	Delorazepam	2754-(1-85)
(14)	Diazepam	2765*
(15)	Dichloralphenazone	2467-(10-02)
(16)	Estazolam	2756-(1-85)
(17)	Ethchlorvynol	2540*
(18)	Ethinamate	2545*
(19)	Ethyl loflazepate	2758-(1-85)

(20)	Fludiazepam	
(21)	Flunitrazepam	2763-(1-85)
(22)	Flurazepam	2767*
(23)	Fospropofol	2138-(11-09)
(24)	Halazepam	2762-(6-82)
(25)	Haloxazolam	
(26)	Ketazolam	
(27)	Loprazolam	2773-(1-85)
(28)	Lorazepam	2885*
(29)	Lormetazepam	
(30)	Mebutamate	2800*
(31)	Medazepam	2836-(1-85)
(32)	Meprobamate	2820*
(33)	Methohexital =	2264*
(34)	Methylphenobarbital (mephorbarbital)	2250*
(35)	Midazolam	
(36)	Nimetazepam	2837-(1-85)
(37)	Nitrazepam	2834-(1-85)
(38)	Nordiazepam	2838-(1-85)
(39)	Oxazepam	2835*
(40)	Oxazolam	2839*
(41)	Paraldehyde	2585*
(42)	Petrichloral	
(43)	Phenobarbital	2285*
(44)	Pinazepam	2883-(1-85)
(45)	Prazepam	2764*
(46)	Quazepam	2881-(11-86)
(47)	Temazepam	2925-(9-81)
(48)	Tetrazepam	2886-(1-85)
(49)	Triazolam	
(50)	Zaleplon	2781-(9-99)
(51)	Zolpidem	2783-(12-93)
(52)	Zopiclone	2784-(01-06)
(53)	Alfaxalone	2731-(02-14)
(54)	Carisoprodol	8192-(4-97)
(55)	Tramadol	9752-(8-07)
(56)	Suvorexant	2223-(8-14)

- (d) **Fenfluramine**: Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:
 - (1) Fenfluramine ----- 1670*
- (e) <u>Stimulants</u>: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

 - (7) Pemoline (including organometallic complexes

	and chelates thereof)	1530*
(9)	Phentermine	1640*
(10)	Pipradrol	1750-(9-81)
	Sibutramine	
(12)	SPA ((-)-1-dimethylamino-1,2,diphenylethane)	1635-(9-81)
(13)	Lorcaserin	1625-(6-13)

(f) Other substances: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts; isomers whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:

(1)	Pentazocine	9709-(4-79)
	Butorphanol	
(3)	Nalbuphine	(4-97)
(1)	Plugadolino perceperante de la companya de la compa	0725

(4) Eluxadoline ----- 9725

Schedule V

- (a) Schedule V shall consist of the drugs and other substances by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.
- (b) Narcotic Drugs: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs and their salts, as set forth below.

 Reserved
- (c) <u>Narcotic drugs containing nonnarcotic active medicinal ingredients.</u> Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs or salts thereof, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:
 - * (1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.
 - * (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.
 - * (3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.
 - * (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
 - * (5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
 - * (6) Not more than 0.5 milligrams of different and not less than 25 micrograms of atropine sulfate per dosage unit.
- (d) <u>Stimulants</u>: unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:
 - (1) Pyrovalerone ----- 1485-(3-88)
 - (2) Ephedrine:a -{-(Methylamino)ethyl}benzene-methanol; (10-95)
 a-{-(methylamino) ethyl}benzyl alcohol;
 2-methylamino-1-phenyl-1-propanol;
 1-phenyl-1-hydroxy-2-methylaminopropane;
 1-phenyl-2-methylaminopropanol;
 a hydroxy-b-methylaminopropylbenzene;

a product which occurs in the Chinese herb Ma Huang (Ephedra vulgaris, Ephedra sinica Stapf., Ephedra equisetina Bunge, Gnetaceae) in several other Ephedra spp.

(3) Phenylpropanolamine ----- (7-05)

(4) Pseudoephedrine ----- (7-05)

Pursuant to Ark. Code Ann. § 5-64-212 as amended in 2005, this Schedule V classification shall NOT apply to any ephedrine, phenylpropanolamine, or pseudoephedrine in liquid, liquid capsule, or liquid gel capsule form. However, sales limits mandated by statute shall apply to all products with ephedrine, phenylpropanolamine, or pseudoephedrine as a listed ingredient regardless of the dosage form.

(e) **Depressants:** Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(2) Lacosamide ----- 2746-(05-09)

(3) Brivaracetam ----- 2710

(f) Other substances:

(1) A drug product in finished dosage formulation that has been approved by the U.S. Food and Drug Administration that contains cannabidiol(2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1, 3-benzenediol) derived from cannabis and no more than 0.1 percent (w/w) residual tetrahydrocannabinols.

Schedule VI**

- (a) In addition to any substance placed in Schedule VI by the Director of the Department of Health under § 5-64-214, any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation, is included in Schedule VI:
 - (1) Marijuana
 - (2) Tetrahydrocannabinols, unless the tetrahydrocannabinol is:
 - (A) Contained in hemp-derived cannabidiol;
 - (B) Not more than three-tenths of one percent (0.3%) of the hempderived cannabidiol on a dry weight basis as verified by a nationally accredited laboratory for quality, purity and accuracy standards; and
 - (C) Not approved by the United States Food and Drug Administration for marketing as a medication;
 - (3) A synthetic equivalent of:
 - (A) The substance contained in the Cannabis plant; or
 - (B) The substance contained in the resinous extractives of the genus Cannabis;
 - (4) Salvia divinorum or Salvinorin A, which includes all parts of the plant presently classified botanically as Salvia divinorum, whether growing or not, the seeds of the plant, any extract from any part of the plant, and every compound, manufacture, derivative, mixture,

- or preparation of the plant, its seeds, or its extracts, including salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation;
- (5) Synthetic substances, derivatives, or their isomers in the chemical structural classes described below in subdivisions (a)(5)(A)-(J) of this section and also specific unclassified substances in subdivision (a)(5)(K) of this section. Compounds of the structures described in this subdivision (a)(5), regardless of numerical designation of atomic positions, are included in this subdivision (a)(5). The synthetic substances, derivatives, or their isomers included in this subdivision (a)(5) are:
 - (A) (i) Tetrahydrocannabinols, including without limitation the following:
 - (a) Delta-1 cis or trans tetrahydrocannabinol, and its optical isomers;
 - (b) Delta-6 cis or trans tetrahydrocannabinol, and its optical isomers; and
 - (c) Delta-3.4 cis or trans tetrahydrocannabinol, and its optical isomers.
 - (ii) Dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the United States Food and Drug Administration is not a tetrahydrocannabinol under this subdivision (a)(5)(A);
 - (B) Naphthoylindoles, or any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following
 - (i) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;
 - (ii) JWH-015, or 1-Propyl-2-methyl-3-(1-naphthoyl)indole;
 - (iii) JWH-018, or 1-Propyl-3-(1-naphthoyl)indole;
 - (iv) JWH-019, or 1-Hexyl-3-(1-naphthoyl)indole;
 - (v) JWH-073, or 1-Butyl-3-(1-naphthoyl)indole;
 - (vi) JWH-081, or 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole;
 - (vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1naphthoyl)indole
 - (viii) JWH-122, or 1-Pentyl-3-(4-methyl-1-naphthoyl)indole;
 - (ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
 - (x) JWH-200, or 1-[2-(4-morpholiny)ethyl]-3-(1-naphthoyl)
 indole;
 - (xi) JWH-210, or 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole;
 - (xii) JWH-398, or 1-Pentyl-3-(4-chloro-1-naphthoyl)indole;
 - (xiii) AM-2201, or 1-(5-fluoropentyl)-3-(1-naphthoyl)indole;
 - (xiv) MAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone; and
 - (xv) EAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone;
 - (xvi) THJ-2201, or [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone;
 - (C) Naphthylmethylindoles, or any compound structurally derived from an H-indol-3-yl-(1-naphthyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or

not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following:

- (i) JWH-175, or 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane; and
- (ii) JWH-184, or 1-Pentyl-1H-3-yl-(4-methyl-1naphthyl)methane;
- (D) Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone;
- (E) Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl) indene with substitution at the 3position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane;
- (F) Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following:
 - (i) JWH-201, or 2-(4-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone;
 - (ii) JWH-203, or 1-Pentyl-3-(2-chlorophenylacetyl)indole;
 - (iii) JWH-250, or 1-Pentyl-3-(2-methoxyphenylacetyl)indole;
 - (iv) JWH-251, or 1-Pentyl-3-(2-methylphenylacetyl)indole; and
 - (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2methoxyphenylacetyl)indole;
- (G) Cyclohexylphenols, or any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent, including without limitation the following:
 - (i) CP 47,497 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3hydroxycyclohexyl]-phenol;
 - (ii) Cannabicyclohexanol or CP 47,497 C8 homologue, or 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol;
 - (iii) CP 55,940, or 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol;
- (H) Benzoylindoles, or any compound structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or

not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following:

- (i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;
- (ii) RCS-4, or 1-Pentyl-3-(4-methoxybenzoyl)indole;
- (iii) WIN-48,098 or Pravadoline, or (4-Methoxyphenyl)-[2methyl-1-(2-(4-morpholinyl)ethyl)indol-3-y]methanone;
- (iv) AM-2233, or 1-[(N-methylpiperidin-2-yl)methyl]-3-(2iodobenzoyl)indole; and
- (v) RCS-4 (C4 homologue) or (4-methoxyphenyl)(1-butyl-1Hindol-3-yl)-methanone;
- (I) Adamantoylindoles, or Adamantoylindazoles, including Adamantyl Carboxamide Indoles and Adamantyl Carboxamide Indazoles, or any compound structurally derived from 3-(1-adamantoyl) indole, 3-(1-adamantoyl) indazole, or 3-(2-adamantoyl)indole by substitution at a nitrogen atom of the indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole or indazole ring to any extent and whether or not substituted in the adamantly ring to any extent, including without limitation the following:
 - (i) AM-1248, or 1-adamantyl-[1-[(1-methylpiperidin-2yl)methyl]indol-3-yl]methanone;
 - (ii) AB-001, or 1-adamantyl-(1-pentylindol-3-yl)methanone;
 - (iii) JWH-018 adamantyl carboxamide, or 1-pentyl-Ntricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide, some other names: 2NE1;
 - (iv) AKB-48, or N-(1-adamantyl)-pentyl-1H-indazole-3carboxamide;
 - (v) 5F-AKB-48, or N-((3s,5s,7s)-adamantan-1-yl)-1-(5fluoropentyl)-1H-indazole-3-carboxamide;
 - (vi) STS-135, or N-(1-adamantyl)-1-(5-fluoropentyl)indole-3carboxamide;
- (J) Tetramethylcyclopropylcarbonylindoles or any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl) indole by substitution at the nitrogen atom of the indole ring with alkyl,haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, including without limitation the following:
 - (i) UR-144, or (1-pentylindol-3-y1)-(2,2,3,3tetramethylcyclopropyl)methanone;
 - (ii) XLR-11, or [1-(5-fluoropentyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone;
 - (iii) A-796,260, or [1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
 - (iv) 5-Chloro-UR-144, or ([-(5-chloropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
 - (v) 5-Bromo-UR-144, or [1-(5-bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; and

- (vi) A-834,735, or 1-(tetrahydropyran-4-ylmethyl)-1H-indol-3yl]-(2,2,3,3-tetramethylcyclopropyl)methanone;
- (K) Unclassified Synthetic Cannabinoids, including without limitation the following:
 - (i) CP 50556-1 hydrochloride, or [(6S,6aR,9R,10aR)-9hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;
 - (ii) HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl3-(2-methyloctan-2-yl)-6a,7,10,10atetrahydrobenzo[c]chromen-1-ol;
 - (iii) HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10atetrahydrobenzo[c]chromen-1-ol;
 - (iv) Dimethylheptylpyran or DMHP;
 - (v) WIN55,212-2, or 2,3-Dihydro-5-methyl-3-(4morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6yl-1-naphthalenylmethanone;

 - (vii) URB754, or 6-methyl-2-[(4-methylphenyl)amino]-1benzoxazin-4-one;

 - (ix) URB602, or cyclohexyl N-(3-phenylphenyl)carbamate;
 - (x) PB-22, or quinolin-8-yl 1-(5-pentyl)-1H-indole-3carboxylate;
 - (xi) 5F-PB-22, or quinolin-8-yl 1-(5-fluoropentyl)-1Hindole-3-carboxylate;
 - (xii) BB-22, or quinolin-8-yl 1-(cyclohexylmethyl)-1Hindole-3-carboxylate;
 - (xiii) NNEI (MN-24), or N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide;
 - (xiv) 5F-NNEI, or 1-(5-fluoropentyl)-N-(naphthalene-1-yl)1H-indole-3-carboxamide;
 - (xv) 5-Fluoro-AMB, or n-[[1-(5-fluoropentyl)-1H-indazol-3yl]carbonyl]-L-valine methyl ester;
 - (xvi) MMB-CHMICA,or methyl-(1-cyclohexylmethyl)-1H-indole-3carbonyl)-L-valinate;
 - (xvii) 5-Fluoro-ADB, or methyl 2-(1-(5-fluoropentyl)-1Hindazole-3-carboxamido)-3,3-dimethylbutanoate;
 - (xviii) 5-Fluoro-MDMB-PICA, or methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;
 - (xix) MDMB-CHMICA, or methyl 2-(1-(cyclohexylmethyl)-1Hindole-3-carboxamido)-3,3-dimethylbutanoate;
 - (xx) FUB-AMB, or methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate;
 - (xxi) MDMB-FUBINACA, or methyl 2-(1-(4-fluorobenzyl)-1Hindazole-3-carboxamido)-3,3-dimethylbutanoate;
 - (xxii) AB-PINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)1-pentyl-1H-indazole-3-caroboxamide;
 - (xxiii) AB-CHMINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide;
 - (xxiv) MAB-CHMINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide;

- (xxv) AB-FUBINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)1-(4-fluorobenzyl)-1H-indazole-3-carboxamide;
- (xxvi) ADB-PINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2yl)-1-pentyl-1H-indazole-3-carboxamide;
- (xxvii) 5F-CUMYL-PINACA, or 1-(5-fluoropentyl)-N-(2phenylpropan-2-yl)-1H-indazole-3-carboxamide.
- 6) A synthetic substance, derivative, or its isomers with:
 - (A) Similar chemical structure to any substance described in subdivisions (a) (1)-(5) of this section; or
 - (B) Similar pharmacological effects to any substance described in subdivisions (a) (1)-(5) of this section.
- (b) However, director shall not delete a controlled substance listed in this section from Schedule ${\tt VI}$.
- (c)(1) If notice has been given to the director that the United States Food and Drug Administration has designated, rescheduled, or descheduled a marijuanaderived substance under federal law and approved for marketing the marijuanaderived substance as a prescription medication, the director shall consider the designation, rescheduling, or descheduling of the marijuanaderived substance under this chapter.
- *-Scheduled before April, 1979.
- **-Schedule VI is revised to conform to Act 329 of 2013.

		243